Teva Pharmaceutical Industries ADR (NY: TEVA )

The stock market rallied last week. The S&P 500 closed 51 points higher, the Dow closed 191 points higher, and the Nasdaq Composite closed 284 points higher. But is the rally real?

Tuesday Talk: What's Going On?

November 14, 2023

Topics Stocks

Exposures US Equities

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

November 13, 2023

From Royalty Pharma plc

Via GlobeNewswire

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

November 13, 2023

The Israel-Hamas War is adversely affecting everything in Israel, including the stock performances of the 15 Israeli companies with market capitalizations of $2B or more that are listed on the Nasdaq...

Israel-Hamas War News: Top 15 Israeli-Based US-Traded Stocks Continue To Slide

November 12, 2023

TEVA earnings call for the period ending September 30, 2023.

Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript

November 08, 2023

Via The Motley Fool

Topics Earnings

Exposures Financial

Teva Pharmaceutical Lifts Revenue Forecast - Huntington's And Migraine Drugs Help Q3 Performance

November 08, 2023

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported Q3 sales of $3.85 billion, beating the consensus of $3.72 billion

Via Benzinga

Teva Closes In On A Buy Point On Third-Quarter Beat, Business Separation

November 08, 2023

The company named a new chief executive for its Teva api business.

US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings

November 08, 2023

Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into...

Via Benzinga

Topics Economy

Exposures Interest Rates

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

November 08, 2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

Earnings Scheduled For November 8, 2023

November 08, 2023

Via Benzinga

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

November 07, 2023

Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting

November 02, 2023

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

November 01, 2023

Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook

October 25, 2023

Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the

Via Benzinga

Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program

October 25, 2023

Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space

October 23, 2023

Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.

The 111 Israeli companies with stocks trading on US exchanges have combined market caps over $150B. Or at least they did midweek: since the Hamas-Israeli War began October 7th, pretty much everything...

Israeli-Hamas War: U.S. Exchange-Listed Israeli Stocks Continue To Decline

October 22, 2023

Israel-focused ETFs have plunged since the last trading day before Hamas launched surprise attacks on Israel, while some Israeli companies listed in the U.S. have so far escaped repercussions to their...

Investor Exit Israel ETFs Following Attacks, But Remain Confident In Large-Caps

October 19, 2023

Via Benzinga

Topics ETFs

Thoughts For Thursday: War Worries Rattle The Market

October 19, 2023

111 Israeli companies trade on U.S. stock exchanges of which only 15 have market capitalization of $2B or more.

Hamas-Israeli War: US Exchange Listed Israeli Stocks Hit Hard

October 18, 2023

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

October 17, 2023

Israel Could Form Emergency Government: Defense Stocks, Israel ETFs In Focus During Conflict

October 10, 2023

As Israel ramps up its armed forces and a regional war with Hamas enters its fourth day, the country is considering forming an emergency government.

Via Benzinga

Topics ETFs

Israeli Stocks Fall as Investors Fear Middle East Conflict

October 09, 2023

The recent attacks on Israel will have a lasting economic impact. Here's what investors should know about Israeli stocks.

Via InvestorPlace

Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch

October 09, 2023

Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil.

Via Benzinga

Topics ETFs

Why Teva Pharmaceutical (TEVA) Stock Is Falling

October 09, 2023

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares are trading lower by 2.7% to $9.17 Monday morning amid conflict in the company's home country, Israel.

Via Benzinga

Middle East War Hammers Israel-Based Stocks But Lifts Defense, Oil Names

October 09, 2023

Israel stocks, regardless of industry, sank Monday following the terrorist attack on Israel.

Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023

October 06, 2023

Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories

October 04, 2023

Benzinga

Via Benzinga

Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.

October 04, 2023

The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.